CytomX Therapeutics (CTMX) News Today $0.66 +0.03 (+4.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.67 +0.01 (+1.52%) As of 04/17/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Altium Capital Management LLC Trims Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Altium Capital Management LLC decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 48.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,491 shares of the biotechnology compaApril 20 at 5:54 AM | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated at StockNews.comApril 17 at 3:49 AM | americanbankingnews.comPiper Sandler Begins Coverage on CytomX Therapeutics (NASDAQ:CTMX)April 16, 2025 | americanbankingnews.comPiper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)April 15, 2025 | markets.businessinsider.comCytomX Therapeutics assumed with an Overweight at Piper SandlerApril 15, 2025 | markets.businessinsider.comCytomX Therapeutics participates in a conference call with JPMorganApril 2, 2025 | markets.businessinsider.comStockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to HoldStockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.April 1, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in MarchCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,000,000 shares, an increase of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 5.0 days.March 29, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 21, 2025 | marketbeat.comSean A. Mccarthy Sells 37,656 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now owns 995,195 shares in the company, valued at $597,117. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 21, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockMarch 21, 2025 | insidertrades.comCytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal yearMarch 14, 2025 | uk.investing.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.March 11, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comCytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of CytomX Therapeutics in a report on Friday.March 8, 2025 | marketbeat.comCytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy NowMarch 7, 2025 | insidermonkey.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 7, 2025 | markets.businessinsider.comCytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comCytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by BrokeragesShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have assigneMarch 5, 2025 | marketbeat.comCytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on ThursdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=351571)March 1, 2025 | marketbeat.comCytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025February 27, 2025 | globenewswire.comCytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 50-Day Moving Average - Here's What HappenedCytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - What's Next?February 26, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Should You Sell?CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Here's What HappenedFebruary 18, 2025 | marketbeat.comCTMX stock touches 52-week low at $0.76 amid market challengesFebruary 11, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company.February 8, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Assenagon Asset Management S.A. reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 63.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,850 shares of the biotechnology company'January 25, 2025 | marketbeat.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 3.9 days.January 19, 2025 | marketbeat.comBay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staffJanuary 15, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy ratinJanuary 14, 2025 | marketbeat.comCytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)January 8, 2025 | markets.businessinsider.comCytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | finanznachrichten.deCytomX Therapeutics (CTMX) Gets a Buy from BarclaysJanuary 7, 2025 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from WedbushJanuary 7, 2025 | markets.businessinsider.comCytomX falls after portfolio shakeup, job cutsJanuary 7, 2025 | msn.comCytomX Therapeutics to Cut 40% of WorkforceJanuary 7, 2025 | marketwatch.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | markets.businessinsider.comPeninsula biotech to lay off 40% of workforce as it restructuresJanuary 7, 2025 | bizjournals.comCytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Tuesday.January 7, 2025 | marketbeat.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 6, 2025 | globenewswire.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expands By 26.2%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 4.8 days.December 31, 2024 | marketbeat.comCytomX heading into ‘major catalyst year,’ says JonesResearchDecember 31, 2024 | markets.businessinsider.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assignDecember 20, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?CytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 200-Day Moving Average - What's Next?December 18, 2024 | marketbeat.comJanus Henderson Group PLC Has $5.70 Million Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Janus Henderson Group PLC decreased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 23.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,809,518 sharesDecember 10, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in NovemberCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 4,440,000 shares, a decline of 21.7% from the October 31st total of 5,670,000 shares. Based on an average daily volume of 809,100 shares, the short-interest ratio is currently 5.5 days.November 30, 2024 | marketbeat.comCytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 27, 2024 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buyNovember 25, 2024 | marketbeat.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.320.58▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼62▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies biote News Today SOPHiA GENETICS News Today Cardiff Oncology News Today Gossamer Bio News Today Design Therapeutics News Today Tevogen Bio News Today TuHURA Biosciences News Today MediWound News Today LifeVantage News Today Eledon Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTMX Stock Free CTMX Stock Alerts